Integrated safety and efficacy of garadacimab for hereditary angioedema prophylaxis across 3 clinical trials: phase 2, pivotal phase 3, and open- label extension studies

被引：0
|
作者：
Magerl, M. [1 ,2 ]
Craig, T. J. [3 ]
Anderson, J. [4 ]
Jacobs, J. S. [5 ]
Tachdjian, R. [6 ]
Farkas, H. [7 ]
Yang, W. H. [8 ]
Staubach, P. [9 ]
Aygoeren-Puersuen, E. [10 ]
Ohsawa, I. [11 ]
Pollen, M. [12 ]
Lawo, J. -P. [13 ]
Bica, M. A. [13 ]
Jacobs, I. [12 ]
机构：
[1] Charite Univ Med Berlin, Inst Allergol, Berlin, Germany
[2] Fraunhofer Inst Translat Med & Pharmacol ITMP Immu, Berlin, Germany
[3] Penn State Univ, Dept Med & Pediat, Allergy Asthma & Immunol, Hershey, PA USA
[4] AllerVie Clin Res, Birmingham, AL USA
[5] Allergy & Asthma Clin Res, Walnut Creek, CA USA
[6] Univ Calif Los Angeles, Div Allergy & Clin Immunol, David Geffen Sch Med, Los Angeles, CA USA
[7] Semmelweis Univ, Hungarian Angioedema Ctr Reference & Excellence, Dept Internal Med & Haematol, Budapest, Hungary
[8] Univ Ottawa, Ottawa Allergy Res Corp, Ottawa, ON, Canada
[9] Univ Med Ctr Mainz, Dept Dermatol & Allergy, Mainz, Germany
[10] Univ Hosp Frankfurt, Dept Children & Adolescents, Frankfurt, Germany
[11] Saiyu Soka Hosp, Dept Nephrol, Saitama, Japan
[12] CSL Behring, King Of Prussia, PA USA
[13] CSL Behring Innovat GmbH, Marburg, Germany
来源：
ALLERGOLOGIE | 2024年 / 47卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P2.9
引用
收藏
页数：55
相关论文
共 50 条
  • [41] Efficacy, safety and pharmacokinetics of icatibant for acute attacks in Japanese adults with type I or type II hereditary angioedema: results of a phase 3, open-label study
    Hide, M.
    Fukunaga, A.
    Maehara, J.
    Yamamoto, F.
    Hao, J.
    Vardi, M.
    Schranz, J.
    Nomoto, Y.
    ALLERGY, 2017, 72 : 149 - 150
  • [42] Evaluation Of Icatibant Reinjection Of Laryngeal Hereditary Angioedema Attacks: A Pooled Analysis Of Three Phase III Open-Label Extension Studies
    Baptista, Jovanna
    Bernstein, Jonathan A.
    Lumry, William R.
    Riedl, Marc A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB36 - AB36
  • [43] Efficacy and Safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF from an integrated analysis of Phase 2 and 3 clinical trials
    Fisher, M.
    Ward, D.
    Crowfoot, G.
    Shamblaw, D.
    Bellos, N.
    Chen, S.
    Rhee, M.
    Aizen, K.
    Szwarcberg, J.
    HIV MEDICINE, 2013, 14 : 55 - 55
  • [44] Lanadelumab efficacy and safety after switching from androgens: analysis of the phase 3 HELP and HELP OLE studies for hereditary angioedema
    Lumry, William
    Johnston, Douglas
    Riedl, Marc
    Choudhry, Zia
    Nurse, Christina
    Yegin, Ashley
    Juethner, Salome
    Banerji, Aleena
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB166 - AB166
  • [45] Preventing Hereditary Angioedema Attacks in Children Using Cinryze®: Interim Efficacy and Safety Phase 3 Findings
    Aygoeren-Puersuen, Emel
    Soteres, Daniel
    Moldovan, Dumitru
    Christensen, Jim
    Van Leerberghe, Arthur
    Hao, James
    Schranz, Jennifer
    Jacobson, Kraig W.
    Martinez-Saguer, Inmaculada
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2017, 173 (02) : 114 - 119
  • [46] Efficacy and safety of Cinryze for the prevention of hereditary angioedema attacks in children: interim results of a Phase 3 study
    Aygoren-Pursun, E.
    Moldovan, D.
    Christensen, J.
    van, Leerberghe A.
    Wu, Y.
    Schranz, J.
    Martinez-Saguer, I
    Soteres, D.
    ALLERGY, 2016, 71 : 296 - 296
  • [47] Icatibant is effective in the treatment of acute attacks of hereditary angioedema: updates on the open-label extension arm of a phase III clinical trial
    Bork, K.
    ALLERGY, 2009, 64 : 281 - 282
  • [48] Open Label Extension of the Phase 3 Study NEURO-TTR to Assess the Long-term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis
    Brannagan, Thomas
    Wang, Annabel K.
    Coelho, Teresa
    Cruz, Marcia Waddington
    Polydefkis, Michael J.
    Dyck, Peter J.
    Scheinberg, Morton
    Plante-Bordeneuve, Violaine
    Berk, John
    Barroso, Fabio
    Adams, David
    Whelan, Carol
    Merlini, Giampaolo
    Drachman, Brian M.
    Heitner, Stephen B.
    Conceicao, Isabel
    Schmidt, Hartmut
    Vita, Giuseppe
    Campistol, Josep M.
    Gamez, Josep
    Gorevic, Peter
    Monia, Brett P.
    Hughes, Steven G.
    Kwoh, Jesse
    McEvoy, Bradley W.
    Baker, Brenda F.
    Ackermann, Elizabeth J.
    Benson, Merrill D.
    Gertz, Morie
    NEUROLOGY, 2018, 90
  • [49] Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Craig, Timothy J.
    Reshef, Avner
    Li, H. Henry
    Jacobs, Joshua S.
    Bernstein, Jonathan A.
    Farkas, Henriette
    Yang, William H.
    Stroes, Erik S. G.
    Ohsawa, Isao
    Tachdjian, Raffi
    Manning, Michael E.
    Lumry, William R.
    Saguer, Inmaculada Martinez
    Aygoeren-Puersuen, Emel
    Ritchie, Bruce
    Sussman, Gordon L.
    Anderson, John
    Kawahata, Kimito
    Suzuki, Yusuke
    Staubach, Petra
    Treudler, Regina
    Feuersenger, Henrike
    Glassman, Fiona
    Jacobs, Iris
    Magerl, Markus
    LANCET, 2023, 401 (10382): : 1079 - 1090
  • [50] Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study
    Fukuda, Tomoo
    Yamagami, Keiko
    Kawahata, Kimito
    Suzuki, Yuzo
    Sasaki, Yoshihiro
    Miyagi, Takashi
    Jacobs, Iris
    Lawo, John-Philip
    Glassman, Fiona
    Akama, Hideto
    Hide, Michihiro
    Ohsawa, Isao
    ALLERGOLOGY INTERNATIONAL, 2023, 72 (03) : 451 - 457
12345